Zealand Pharma A/S, a pharmaceutical company based in Denmark, focuses on developing peptide-based medicines. With a medium ESG score of 27.0, the company's product pipeline includes treatments for short bowel syndrome, diabetes management, and congenital hyperinsulinism. Zealand Pharma has also collaborated with Boehringer Ingelheim on a novel dual-acting GLP-1/glucagon agonist for obesity and Type 2 diabetes.